These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21663575)

  • 1. Newer therapeutic vistas for antiglaucoma medicines.
    Kaur IP; Kakkar S
    Crit Rev Ther Drug Carrier Syst; 2011; 28(2):165-202. PubMed ID: 21663575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glaucoma: Current treatment and impact of advanced drug delivery systems.
    Yadav KS; Rajpurohit R; Sharma S
    Life Sci; 2019 Mar; 221():362-376. PubMed ID: 30797820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
    Babizhayev MA
    Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiglaucoma carbonic anhydrase inhibitors: a patent review.
    Masini E; Carta F; Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2013; 23(6):705-16. PubMed ID: 23627893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in pharmacotherapy of glaucoma.
    Gupta SK; Niranjan D G; Agrawal SS; Srivastava S; Saxena R
    Indian J Pharmacol; 2008 Oct; 40(5):197-208. PubMed ID: 20040958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy.
    Hiett JA; Dockter CA
    Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contemporary possibilities and perspectives in the treatment of glaucoma].
    Czepita D
    Ann Acad Med Stetin; 2005; 51(1):27-31. PubMed ID: 16496599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glaucoma and the applications of carbonic anhydrase inhibitors.
    Scozzafava A; Supuran CT
    Subcell Biochem; 2014; 75():349-59. PubMed ID: 24146387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for ocular hypertension.
    Lee AJ; Goldberg I
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):137-61. PubMed ID: 21352074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines for the treatment of glaucoma: Current status and future perspectives.
    Zhai Z; Cheng Y; Hong J
    Acta Biomater; 2021 Apr; 125():41-56. PubMed ID: 33601065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
    Hommer A
    Drugs Today (Barc); 2010 Jun; 46(6):409-16. PubMed ID: 20571609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of antiglaucoma and systemic medications on ocular blood flow.
    Costa VP; Harris A; Stefánsson E; Flammer J; Krieglstein GK; Orzalesi N; Heijl A; Renard JP; Serra LM
    Prog Retin Eye Res; 2003 Nov; 22(6):769-805. PubMed ID: 14575724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuro-hormonal regulation of aqueous humor dynamics as the basis of glaucoma pharmacotherapy. Part I. Aqueous humor secretion].
    Terelak-Borys B; Liberek I
    Klin Oczna; 2007; 109(1-3):60-3. PubMed ID: 17687916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management.
    Yang H; Leffler CT
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):166-72. PubMed ID: 23249385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019).
    Nocentini A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):805-815. PubMed ID: 31486689
    [No Abstract]   [Full Text] [Related]  

  • 17. Hazards of medical glaucoma therapy in the cataract patient.
    Van Buskirk EM
    Ophthalmology; 1982 Mar; 89(3):238-41. PubMed ID: 6123971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019.
    Supuran CT; Altamimi ASA; Carta F
    Expert Opin Ther Pat; 2019 Oct; 29(10):781-792. PubMed ID: 31596641
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel therapies for glaucoma: a patent review 2007 - 2011.
    Carta F; Supuran CT; Scozzafava A
    Expert Opin Ther Pat; 2012 Jan; 22(1):79-88. PubMed ID: 22191414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
    Angeli A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.